Literature DB >> 21439986

A question of balance--positive versus negative allosteric modulation of GABA(A) receptor subtypes as a driver of analgesic efficacy in rat models of inflammatory and neuropathic pain.

Gordon Munro1, Helle K Erichsen, Mark G Rae, Naheed R Mirza.   

Abstract

After injury GABA(A) receptor positive allosteric modulators (PAMs) mediate robust analgesia in animals via putative restoration of post-synaptic GABA(A)-α2 and -α3 receptor function within the spinal cord. GABA can also act at GABA(A) receptors localized on primary afferent neurones to inhibit presynaptic neurotransmitter release and produce analgesia via a process called primary afferent depolarization (PAD). Some forms of injury might sufficiently enhance PAD to shift it into a net excitatory process. Thus, negative allosteric modulators (NAMs) might also possess analgesic activity. We have compared compounds capable of either positively or negatively modulating GABA(A) receptors in rat models associated with injury-induced central sensitization. The subtype-selective PAMs NS11394 (1-10 mg/kg) and TPA023 (3-30 mg/kg) attenuated formalin-induced nocifensive behaviours. Similarly, both compounds reversed hindpaw mechanical hypersensitivity and weight bearing deficits in carrageenan-inflamed and nerve-injured rats. The non-selective PAM diazepam (1-5 mg/kg) was ineffective in all models. Surprisingly, both the non-selective NAM FG-7142 (3-30 mg/kg) and the α5-selective NAM α5IA-II (10-60 mg/kg) also attenuated formalin-induced nocifensive behaviours. In carrageenan-inflamed rats α5IA-II reversed mechanical hypersensitivity and weight bearing deficits whilst FG-7142 only attenuated weight bearing deficits. This picture was essentially reversed in nerve-injured rats for these two NAMs. With the exception of NS11394, all compounds attenuated exploratory motility behaviour in rats, either as a consequence of sedative or anxiogenic-like side-effects. These data indicate that the preferred selectivity and activity profiles for mediating analgesia upon activation of GABA(A) receptors might be more complex than previously anticipated, and is worthy of further exploration.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21439986     DOI: 10.1016/j.neuropharm.2011.03.017

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  17 in total

1.  The α7 nicotinic ACh receptor agonist compound B and positive allosteric modulator PNU-120596 both alleviate inflammatory hyperalgesia and cytokine release in the rat.

Authors:  G Munro; Rr Hansen; Hk Erichsen; Db Timmermann; Jk Christensen; Hh Hansen
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 2.  GABA pharmacology: the search for analgesics.

Authors:  Kenneth E McCarson; S J Enna
Journal:  Neurochem Res       Date:  2014-02-15       Impact factor: 3.996

3.  Transmission pathways and mediators as the basis for clinical pharmacology of pain.

Authors:  Daniel R Kirkpatrick; Dan M McEntire; Tyler A Smith; Nicholas P Dueck; Mitchell J Kerfeld; Zakary J Hambsch; Taylor J Nelson; Mark D Reisbig; Devendra K Agrawal
Journal:  Expert Rev Clin Pharmacol       Date:  2016-07-04       Impact factor: 5.045

4.  Increased anxiety-like behaviors in rats experiencing chronic inflammatory pain.

Authors:  Alexandre J Parent; Nicolas Beaudet; Hélène Beaudry; Jenny Bergeron; Patrick Bérubé; Guy Drolet; Philippe Sarret; Louis Gendron
Journal:  Behav Brain Res       Date:  2012-01-08       Impact factor: 3.332

5.  Pharmacokinetic/Pharmacodynamic Relationship of Gabapentin in a CFA-induced Inflammatory Hyperalgesia Rat Model.

Authors:  Malte Selch Larsen; Ron Keizer; Gordon Munro; Arne Mørk; René Holm; Rada Savic; Mads Kreilgaard
Journal:  Pharm Res       Date:  2016-01-15       Impact factor: 4.200

Review 6.  Therapeutic Basis of Clinical Pain Modulation.

Authors:  Daniel R Kirkpatrick; Dan M McEntire; Zakary J Hambsch; Mitchell J Kerfeld; Tyler A Smith; Mark D Reisbig; Charles F Youngblood; Devendra K Agrawal
Journal:  Clin Transl Sci       Date:  2015-05-11       Impact factor: 4.689

Review 7.  Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes.

Authors:  Uwe Rudolph; Frédéric Knoflach
Journal:  Nat Rev Drug Discov       Date:  2011-07-29       Impact factor: 84.694

Review 8.  α2-containing GABA(A) receptors: a target for the development of novel treatment strategies for CNS disorders.

Authors:  Elif Engin; Jing Liu; Uwe Rudolph
Journal:  Pharmacol Ther       Date:  2012-08-18       Impact factor: 12.310

9.  Expression of gamma-aminobutyric acid type A receptor α2 subunit in the dorsal root ganglion of rats with sciatic nerve injury.

Authors:  Yu Lian; Yang Wang; Ketao Ma; Lei Zhao; Zhongshuang Zhang; Yuanyuan Shang; Junqiang Si; Li Li
Journal:  Neural Regen Res       Date:  2012-11-15       Impact factor: 5.135

10.  The Effect of Intrathecal Administration of Muscimol on Modulation of Neuropathic Pain Symptoms Resulting from Spinal Cord Injury; an Experimental Study.

Authors:  Marjan Hosseini; Zohreh Karami; Atousa Janzadenh; Seyed Behnamedin Jameie; Zahra Haji Mashhadi; Mahmoud Yousefifard; Farinaz Nasirinezhad
Journal:  Emerg (Tehran)       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.